MXCT vs. HRTX, MGTX, ANAB, MGNX, NRC, OABI, ABSI, HBIO, LUNA, and NOTV
Should you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include Heron Therapeutics (HRTX), MeiraGTx (MGTX), AnaptysBio (ANAB), MacroGenics (MGNX), National Research (NRC), OmniAb (OABI), Absci (ABSI), Harvard Bioscience (HBIO), Luna Innovations (LUNA), and Inotiv (NOTV).
Heron Therapeutics (NASDAQ:HRTX) and MaxCyte (NASDAQ:MXCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
Heron Therapeutics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
Heron Therapeutics received 646 more outperform votes than MaxCyte when rated by MarketBeat users. However, 84.62% of users gave MaxCyte an outperform vote while only 69.01% of users gave Heron Therapeutics an outperform vote.
Heron Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 48.65%. MaxCyte has a consensus target price of $8.67, indicating a potential upside of 93.45%. Given Heron Therapeutics' higher possible upside, analysts clearly believe MaxCyte is more favorable than Heron Therapeutics.
Heron Therapeutics has a net margin of -61.28% compared to Heron Therapeutics' net margin of -83.00%. MaxCyte's return on equity of 0.00% beat Heron Therapeutics' return on equity.
MaxCyte has lower revenue, but higher earnings than Heron Therapeutics. MaxCyte is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Heron Therapeutics had 7 more articles in the media than MaxCyte. MarketBeat recorded 9 mentions for Heron Therapeutics and 2 mentions for MaxCyte. Heron Therapeutics' average media sentiment score of 0.93 beat MaxCyte's score of 0.66 indicating that MaxCyte is being referred to more favorably in the news media.
80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 6.4% of Heron Therapeutics shares are held by company insiders. Comparatively, 3.0% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Heron Therapeutics beats MaxCyte on 9 of the 17 factors compared between the two stocks.
Get MaxCyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
